Skip to main content
Premium Trial:

Request an Annual Quote

Alexion, Boston Univ. Develop High-Throughput Microarray Technology

Premium

N

EW HAVEN, Conn.--Alexion Pharmaceuticals announced that it has reached a milestone in the development of a novel, miniaturized, silicon-based microarray assay technology aimed at enhancing its internal drug discovery efforts. Working collaboratively with Boston University’s Department of Electrical and Computer Engineering, Alexion has established the capability to perform nanoliter volume microassays with a miniaturized, software-driven robotic system.

Stephen Squinto, Alexion’s chief technology officer, said the technology may have particular utility in areas such as genomics, single-nucleotide polymorphisms, proteomics, and screening of large recombinant protein libraries, including antibodies.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.